Refractory Anaplastic Large Cell Lymphoma (DBCOND0078800)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Crizotinib	A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive.	Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter ALK tyrosine kinase receptortarget Hepatocyte growth factor receptortarget Cytochrome P450 2B6enzyme Cytochrome P450 3A Subfamilyenzyme Albumincarrier alpha1-acid glycoproteincarrier Proto-oncogene tyrosine-protein kinase ROStarget Macrophage-stimulating protein receptortarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	AFM-13 Acimtamig Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT03075553	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Nivolumab	treatment	2	terminated
NCT00939770	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Crizotinib Tyrosine	treatment	1 / 2	completed
NCT03278782	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin	Pembrolizumab Romidepsin	treatment	1 / 2	active_not_recruiting
NCT04774068	Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas	Parsaclisib Romidepsin	treatment	1	active_not_recruiting
NCT02572453	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	Onalespib	treatment	2	terminated
NCT03598998	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Pembrolizumab Pralatrexate	treatment	1 / 2	active_not_recruiting
NCT01787409	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	No drug interventions	treatment	Not Available	recruiting
NCT01590732	Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ifosfamide Romidepsin	treatment	1	completed
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Nivolumab Talimogene laherparepvec	treatment	2	active_not_recruiting
NCT03017820	VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	Cemiplimab Cyclophosphamide Human interferon beta Sodium iodide	treatment	1	recruiting